Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEBT-209 in Combination With Carboplatin and Gemcitabine for Advanced Triple-Negative Breast Cancer
NCT06685796Phase 2Completed
- Sponsor
- BeBetter Med
- Start
- Apr 2023
- Primary completion
- Apr 2026
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bebt-209 in triple-negative breast cancer (TNBC) (3 cohorts), sponsored by BeBetter Med. Primary endpoints: Progression-Free Survival at 24 months and Adverse Events. Started Apr 2023; status: completed.
02
Drugs
bebt-209
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06685796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06685796.